XENT - Intersect ENT provides preliminary Q3 figures

Intersect ENT (XENT) expects Q3 revenue to be $22.4M-22.8M.SINUVA expected to achieve strongest quarterly revenue to date of ~$1.7M.Cash and marketable securities are expected to be ~$130M.Thomas A. West, President and CEO comments: "Our solid third quarter preliminary revenue reflects a continuation of increased sequential sinus surgery procedure demand leading to strong volumes of PROPEL, with notable year-on-year growth of PROPEL in the office setting. This was also the highest quarterly revenue performance for SINUVA since its launch reflecting our improved payer position and emerging strength in ENT in-office procedures."Previously: Intersect scoops up Fiagon for €60M (Sept. 15)

For further details see:

Intersect ENT provides preliminary Q3 figures